The DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.
Breast cancer: Biology, biomarkers, and treatments
Abstract
During the past recent years, various therapies emerged in the era of breast cancer. Breast cancer is a heterogeneous disease in which genetic and environmental factors are involved. Breast cancer stem cells (BCSCs) are the main player in the aggressiveness of different tumors and also, these cells are the main challenge in cancer treatment. Moreover, the major obstacle to achieve an effective treatment is resistance to therapies. There are various types of treatment for breast cancer (BC) patients. Therefore, in this review, we present the current treatments, novel approaches such as antibody-drug conjugation systems (ADCs), nanoparticles (albumin-, metal-, lipid-, polymer-, micelle-based nanoparticles), and BCSCs-based therapies. Furthermore, prognostic and predictive biomarkers will be discussed also biomarkers that have been applied by some tests such as Oncotype DX, Mamm αPrint, and uPA/PAI-1 are regarded as suitable prognostic and predictive factors in breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M. A., & Dick, J. E. (1994) · Nature · doi:10.1038/367645a0 · Cited by 4,783
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206
Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4147 · Cited by 2,892
Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases
Carter, C. L., Allen, C., & Henson, D. E. (1989) · Cancer · doi:10.1002/1097-0142(19890101)63:1<181::aid-cncr2820630129>3.0.co;2-h · Cited by 2,288
Evolution of the Cancer Stem Cell Model
Kreso, A., & Dick, J. E. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.02.006 · Cited by 2,224
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039
Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Chronic inflammation and cytokines in the tumor microenvironment
Landskron, G., De la Fuente, M., Thuwajit, P., Thuwajit, C., & Hermoso, M. A. (2014) · Journal of Immunology Research · doi:10.1155/2014/149185 · Cited by 1,765
DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715
Combining immunotherapy and targeted therapies in cancer treatment
Vanneman, M., & Dranoff, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3237 · Cited by 1,586
Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors
Din, F. U., Aman, W., Ullah, I., Qureshi, O. S., Mustapha, O., Shafique, S., & Zeb, A. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s146315 · Cited by 1,577
Immunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
A distinct “side population” of cells with high drug efflux capacity in human tumor cells
Hirschmann-Jax, C., Foster, A. E., Wulf, G. G., Nuchtern, J. G., Jax, T. W., Gobel, U., Goodell, M. A., & Brenner, M. K. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400067101 · Cited by 1,280
Buyse, M., Loi, S., van't Veer, L., Viale, G., Delorenzi, M., Glas, A. M., Saghatchian d'Assignies, M., Bergh, J., Lidereau, R., Ellis, P., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj329 · Cited by 1,238
Ogitani, Y., Aida, T., Hagihara, K., Yamaguchi, J., Ishii, C., Harada, N., Soma, M., Okamoto, H., Oitate, M., Arakawa, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2822 · Cited by 1,177
Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma
Von Hoff, D. D., LoRusso, P. M., Rudin, C. M., Reddy, J. C., Yauch, R. L., Tibes, R., Weiss, G. J., Borad, M. J., Hann, C. L., Brahmer, J. R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905360 · Cited by 1,109
Kobayashi, H., Watanabe, R., & Choyke, P. L. (2014) · Theranostics · doi:10.7150/thno.7193 · Cited by 996
Prospects for combining targeted and conventional cancer therapy with immunotherapy
Gotwals, P., Cameron, S., Cipolletta, D., Cremasco, V., Crystal, A., Hewes, B., Mueller, B., Quaratino, S., Sabatos-Peyton, C., Petruzzelli, L., et al. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.17 · Cited by 953
Combination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944
Bracci, L., Schiavoni, G., Sistigu, A., & Belardelli, F. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.67 · Cited by 928
Zitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.014 · Cited by 870
Harris, L. N., Ismaila, N., McShane, L. M., Andre, F., Collyar, D. E., Gonzalez-Angulo, A. M., Hammond, E. H., Kuderer, N. M., Liu, M. C., Mennel, R. G., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.2289 · Cited by 811
Cuzick, J., Dowsett, M., Pineda, S., Wale, C., Salter, J., Quinn, E., Zabaglo, L., Mallon, E., Green, A. R., Ellis, I. O., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.2835 · Cited by 739
Survival of the Fittest: Cancer Stem Cells in Therapeutic Resistance and Angiogenesis
Eyler, C. E., & Rich, J. N. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.1829 · Cited by 737
MYC/PGC-1α Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells
Sancho, P., Burgos-Ramos, E., Tavera, A., Bou Kheir, T., Jagust, P., Schoenhals, M., Barneda, D., Sellers, K., Campos-Olivas, R., Graña, O., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.08.015 · Cited by 722
The secret ally: immunostimulation by anticancer drugs
Galluzzi, L., Senovilla, L., Zitvogel, L., & Kroemer, G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3626 · Cited by 670
Progesterone receptor modulates ERα action in breast cancer
Mohammed, H., Russell, I. A., Stark, R., Rueda, O. M., Hickey, T. E., Tarulli, G. A., Serandour, A. A., Birrell, S. N., Bruna, A., Saadi, A., et al. (2015) · Nature · doi:10.1038/nature14583 · Cited by 659
Prognostic and Predictive Factors in Early-Stage Breast Cancer
Cianfrocca, M., & Goldstein, L. J. (2004) · The Oncologist · doi:10.1634/theoncologist.9-6-606 · Cited by 637
Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks
Liu, S., Ginestier, C., Ou, S. J., Clouthier, S. G., Patel, S. H., Monville, F., Korkaya, H., Heath, A., Dutcher, J., Kleer, C. G., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-0538 · Cited by 611
Predicting Response to Endocrine Therapy in Human Breast Cancer: A Hypothesis
Horowitz, K. B., McGuire, W. L., Pearson, O. H., & Segaloff, A. (1975) · Science · doi:10.1126/science.168640 · Cited by 569
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
Emens, L. A., Ascierto, P. A., Darcy, P. K., Demaria, S., Eggermont, A. M. M., Redmond, W. L., Seliger, B., & Marincola, F. M. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.035 · Cited by 566
Miller, T. W., Hennessy, B. T., González-Angulo, A. M., Fox, E. M., Mills, G. B., Chen, H., Higham, C., García-Echeverría, C., Shyr, Y., & Arteaga, C. L. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41680 · Cited by 551
Lipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatment
García-Pinel, B., Porras-Alcalá, C., Ortega-Rodríguez, A., Sarabia, F., Prados, J., Melguizo, C., & López-Romero, J. M. (2019) · Nanomaterials · doi:10.3390/nano9040638 · Cited by 527
Regulation of mammary stem/progenitor cells by PTEN/Akt/β-catenin signaling
Korkaya, H., Paulson, A., Charafe-Jauffret, E., Ginestier, C., Brown, M., Dutcher, J., Clouthier, S. G., & Wicha, M. S. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000121 · Cited by 523
Duffy, M. J., Harbeck, N., Nap, M., Molina, R., Nicolini, A., Senkus, E., & Cardoso, F. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.017 · Cited by 522
An, F.-F., & Zhang, X.-H. (2017) · Theranostics · doi:10.7150/thno.19365 · Cited by 436
Yardley, D. A., Ismail-Khan, R. R., Melichar, B., Lichinitser, M., Munster, P. N., Klein, P. M., Cruickshank, S., Miller, K. D., Lee, M. J., & Trepel, J. B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.7251 · Cited by 423
Wnt signaling controls the fate of mesenchymal stem cells
Ling, L., Nurcombe, V., & Cool, S. M. (2009) · Gene · doi:10.1016/j.gene.2008.12.008 · Cited by 417
Lim, P. K., Bliss, S. A., Patel, S. A., Taborga, M., Dave, M. A., Gregory, L. A., Greco, S. J., Bryan, M., Patel, P. S., & Rameshwar, P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2372 · Cited by 416
Molecular aspects of cancer cell resistance to chemotherapy
Rebucci, M., & Michiels, C. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.02.017 · Cited by 407
Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis
Tian, H., Callahan, C. A., DuPree, K. J., Darbonne, W. C., Ahn, C. P., Scales, S. J., & de Sauvage, F. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813203106 · Cited by 404
Current Landscape of Immunotherapy in Breast Cancer: A Review
Adams, S., Gatti-Mays, M. E., Kalinsky, K., Korde, L. A., Sharon, E., Amiri-Kordestani, L., Bear, H., McArthur, H. L., Frank, E., Perlmutter, J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.7147 · Cited by 384
Recent Advances in Drug Repositioning for the Discovery of New Anticancer Drugs
Shim, J. S., & Liu, J. O. (2014) · International Journal of Biological Sciences · doi:10.7150/ijbs.9224 · Cited by 382
Clinical utility of cytokeratins as tumor markers
Barak, V., Goike, H., Panaretakis, K. W., & Einarsson, R. (2004) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2004.05.009 · Cited by 382
Recent advances in metal nanoparticles in cancer therapy
Sharma, A., Goyal, A. K., & Rath, G. (2018) · Journal of Drug Targeting · doi:10.1080/1061186x.2017.1400553 · Cited by 341
Multifunctional Micellar Nanomedicine for Cancer Therapy
Blanco, E., Kessinger, C. W., Sumer, B. D., & Gao, J. (2009) · Experimental Biology and Medicine · doi:10.3181/0808-mr-250 · Cited by 332
Croker, A. K., & Allan, A. L. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1692-y · Cited by 327
Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy
Wu, J., & Waxman, D. J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.050 · Cited by 320
Antibody–Drug Conjugates for Cancer Treatment
Lambert, J. M., & Berkenblit, A. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-061516-121357 · Cited by 314
Immunogenic effects of chemotherapy-induced tumor cell death
Wang, Y.-J., Fletcher, R., Yu, J., & Zhang, L. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.05.003 · Cited by 314
Delivering safer immunotherapies for cancer
Milling, L., Zhang, Y., & Irvine, D. J. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.011 · Cited by 305
Pramanik, D., Campbell, N. R., Karikari, C., Chivukula, R., Kent, O. A., Mendell, J. T., & Maitra, A. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0152 · Cited by 296
Petrelli, F., Viale, G., Cabiddu, M., & Barni, S. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3559-0 · Cited by 286
Cancer stem cells: A review from origin to therapeutic implications
Atashzar, M. R., Baharlou, R., Karami, J., Abdollahi, H., Rezaei, R., Pourramezan, F., & Zoljalali Moghaddam, S. H. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29044 · Cited by 281
Self-citationBueno-de-Mesquita, J. M., van Harten, W. H., Retel, V. P., van 't Veer, L. J., van Dam, F. S., Karsenberg, K., Douma, K. F., van Tinteren, H., Peterse, J. L., Wesseling, J., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70346-7 · Cited by 274
Cancer stem cells (CSCs): metabolic strategies for their identification and eradication
De Francesco, E. M., Sotgia, F., & Lisanti, M. P. (2018) · Biochemical Journal · doi:10.1042/bcj20170164 · Cited by 269
Targeting HER2 for the Treatment of Breast Cancer
Rimawi, M. F., Schiff, R., & Osborne, C. K. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-042513-015127 · Cited by 268
The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer
Knauer, M., Mook, S., Rutgers, E. J. T., Bender, R. A., Hauptmann, M., van de Vijver, M. J., Koornstra, R. H. T., Bueno-de-Mesquita, J. M., Linn, S. C., & van ’t Veer, L. J. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0814-2 · Cited by 267
Antibody–drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes
Abdollahpour‐Alitappeh, M., Lotfinia, M., Gharibi, T., Mardaneh, J., Farhadihosseinabadi, B., Larki, P., Faghfourian, B., Sepehr, K. S., Abbaszadeh‐Goudarzi, K., Abbaszadeh‐Goudarzi, G., et al. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27419 · Cited by 249
Induction of pluripotent stem cells from mouse fibroblasts by four transcription factors
Yamanaka, S. (2008) · Cell Proliferation · doi:10.1111/j.1365-2184.2008.00493.x · Cited by 241
Cancer immunotherapy: broadening the scope of targetable tumours
van den Bulk, J., Verdegaal, E. M., & de Miranda, N. F. (2018) · Open Biology · doi:10.1098/rsob.180037 · Cited by 240
Tumor-related prognostic factors for breast cancer
Donegan, W. L. (1997) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.47.1.28 · Cited by 228
Burke, A. R., Singh, R. N., Carroll, D. L., Wood, J. C. S., D’Agostino, R. B., Ajayan, P. M., Torti, F. M., & Torti, S. V. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2011.12.052 · Cited by 227
A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study
Drukker, C. A., Bueno‐de‐Mesquita, J. M., Retèl, V. P., van Harten, W. H., van Tinteren, H., Wesseling, J., Roumen, R. M. H., Knauer, M., van 't Veer, L. J., Sonke, G. S., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28082 · Cited by 227
Serum CEA and CA 15-3 as prognostic factors in primary breast cancer
Ebeling, F. G., Stieber, P., Untch, M., Nagel, D., Konecny, G. E., Schmitt, U. M., Fateh-Moghadam, A., & Seidel, D. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600248 · Cited by 215
Nanomedicine applications in the treatment of breast cancer: current state of the art
Wu, D., Si, M., Xue, H.-Y., & Wong, H. L. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s123437 · Cited by 207
Cancer Stem Cells and Chemosensitivity
Maugeri-Saccà, M., Vigneri, P., & De Maria, R. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2538 · Cited by 201
Epigenetic alterations involved in cancer stem cell reprogramming
Muñoz, P., Iliou, M. S., & Esteller, M. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.10.006 · Cited by 200
Antibody–drug conjugates—A new wave of cancer drugs
Bouchard, H., Viskov, C., & Garcia-Echeverria, C. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.10.021 · Cited by 190
Breast cancer chemoresistance: Emerging importance of cancer stem cells
Chuthapisith, S., Eremin, J., El-Sheemey, M., & Eremin, O. (2010) · Surgical Oncology · doi:10.1016/j.suronc.2009.01.004 · Cited by 174
Sharkey, R. M., McBride, W. J., Cardillo, T. M., Govindan, S. V., Wang, Y., Rossi, E. A., Chang, C.-H., & Goldenberg, D. M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0670 · Cited by 172
Metronomic chemotherapy and immunotherapy in cancer treatment
Chen, Y.-L., Chang, M.-C., & Cheng, W.-F. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.01.040 · Cited by 162
Optimal management of hormone receptor positive metastatic breast cancer in 2016
Reinert, T., & Barrios, C. H. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015608993 · Cited by 158
Nanomedicines for Cancer Therapy: Current status, Challenges and Future Prospects
Bor, G., Azmi, I. D. M., & Yaghmur, A. (2019) · Therapeutic Delivery · doi:10.4155/tde-2018-0062 · Cited by 157
Pasquier, E., André, N., & Braguer, D. (2007) · Current Cancer Drug Targets · doi:10.2174/156800907781662266 · Cited by 149
Deciphering the divergent roles of progestogens in breast cancer
Carroll, J. S., Hickey, T. E., Tarulli, G. A., Williams, M. R., & Tilley, W. D. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.116 · Cited by 148
The Use of Nanoparticulates to Treat Breast Cancer
Tang, X., Loc, W. S., Dong, C., Matters, G. L., Butler, P. J., KESTER, M. A., Meyers, C., Jiang, Y., & Adair, J. H. (2017) · Nanomedicine · doi:10.2217/nnm-2017-0202 · Cited by 146
Metabolic features of cancer stem cells: the emerging role of lipid metabolism
Mancini, R., Noto, A., Pisanu, M. E., Vitis, C. D., Maugeri‐Saccà, M., & Ciliberto, G. (2018) · Oncogene · doi:10.1038/s41388-018-0141-3 · Cited by 146
Immune Landscape of Breast Cancers
Nagarajan, D., & McArdle, S. (2018) · Biomedicines · doi:10.3390/biomedicines6010020 · Cited by 142
Uyttendaele, H., Soriano, J. V., Montesano, R., & Kitajewski, J. (1998) · Developmental Biology · doi:10.1006/dbio.1998.8863 · Cited by 130
Wildiers, H. P. M. W., Tryfonidis, K., Lago, L. D., Vuylsteke, P., Curigliano, G., Waters, S. H., Brouwers, B. A. H., Altıntaş, S., Touati, N., Cardoso, F., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30083-4 · Cited by 130
Li, S.-Y., Sun, R., Wang, H., Shen, S., Liu, Y., Du, X., Zhu, Y., & Jun, W. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.11.011 · Cited by 128
NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia
Real, P. J., & Ferrando, A. A. (2009) · Leukemia · doi:10.1038/leu.2009.75 · Cited by 128
Sun, R., Shen, S., Zhang, Y., Xu, C., Cao, Z., Wen, L., & Wang, J. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.06.038 · Cited by 116
Metronomic chemotherapy for cancer treatment: a decade of clinical studies
Romiti, A., Cox, M. C., Sarcina, I., Rocco, R. D., D’Antonio, C., Barucca, V., & Marchetti, P. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2125-x · Cited by 112
EJE PRIZE 2016: Mechanisms of oestrogen receptor (ER) gene regulation in breast cancer
Carroll, J. S. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0124 · Cited by 96
Economopoulou, P., Kaklamani, V., & Siziopikou, K. P. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0163 · Cited by 87
Validated biomarkers: The key to precision treatment in patients with breast cancer
Duffy, M. J., O’Donovan, N., McDermott, E. W. M., & Crown, J. P. (2016) · The Breast · doi:10.1016/j.breast.2016.07.009 · Cited by 85
Breast Cancer Immunotherapy: An Update
Makhoul, I., Atiq, M. O., Alwbari, A. M., & Kieber‐Emmons, T. (2018) · Breast Cancer Basic and Clinical Research · doi:10.1177/1178223418774802 · Cited by 85
High cell-surface density of HER2 deforms cell membranes
Chung, I., Reichelt, M., Shao, L., Akita, R. W., Koeppen, H., Rangell, L. K., Schaefer, G., Mellman, I., & Sliwkowski, M. X. (2016) · Nature Communications · doi:10.1038/ncomms12742 · Cited by 82
Kareva, I. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102134 · Cited by 80
Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review
Ponde, N. F., Aftimos, P. G., & Piccart, M. J. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0633-6 · Cited by 80
Antonioli, L., Novitskiy, S. V., Sachsenmeier, K. F., Fornai, M., Blandizzi, C., & Haskó, G. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.06.005 · Cited by 77
Moes, J. J., Koolen, S. L. W., Huitema, A. D. R., Schellens, J. H. M., Beijnen, J. H., & Nuijen, B. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.09.016 · Cited by 76
Danger signals: Chemotherapy enhancers?
Vargas, T. R., & Apétoh, L. (2017) · Immunological Reviews · doi:10.1111/imr.12581 · Cited by 76
Targeting cancer stem cells by using the nanoparticles
An, S. S. A., Jang, G.-B., Lee, H., Hong, I., & Nam, J. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s88310 · Cited by 74
Targeting stem cells in the realm of drug-resistant breast cancer
Dey, P., Rathod, M., & De, A. (2019) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s189224 · Cited by 73
The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer
Shah, A. N., & Cristofanilli, M. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0443-7 · Cited by 71
Breast Cancer Immunology and Immunotherapy
de la Cruz‐Merino, L., Chiesa, M., Caballero, R., Rojo, F., Carrión, N. P., Carrasco, F. H., & Sánchez‐Margalet, V. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.09.008 · Cited by 70
Francesco, E. M. D., Maggiolini, M., Tanowitz, H. B., Sotgia, F., & Lisanti, M. P. (2017) · Oncotarget · doi:10.18632/oncotarget.18445 · Cited by 65
How can nanotechnology help the fight against breast cancer?
Avitabile, E., Bedognetti, D., Ciofani, G., Bianco, A., & Delogu, L. G. (2018) · Nanoscale · doi:10.1039/c8nr02796j · Cited by 61
Targeting Cancer using Polymeric Nanoparticle mediated Combination Chemotherapy
Gad, A. (2016) · International Journal of Nanomedicine and Nanosurgery · doi:10.16966/2470-3206.116 · Cited by 57
Chen, X., Xu, D., Li, X., Zhang, J., Xu, W., Hou, J., Zhang, W., & Tang, J. (2019) · Journal of Cancer · doi:10.7150/jca.33079 · Cited by 56
Molecular Testing in Breast Cancer
Paoletti, C., & Hayes, D. F. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-070912-143853 · Cited by 53
Adapting conventional cancer treatment for immunotherapy
Qiao, J., Liu, Z., & Fu, Y. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1393-4 · Cited by 48
Yeo, B. J., Zabaglo, L. A., Hills, M., Dodson, A. R., Smith, I., & Dowsett, M. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.222 · Cited by 44
Khan, U. A., Bhavsar, A., Asif, H., Karabatsou, K., Leggate, J. R. S., Sofat, A., & Kamaly-Asl, I. D. (2014) · Journal of neurosurgery · doi:10.3171/2014.10.jns132057 · Cited by 41
Efficient down-regulation of CDK4 by novel lipid nanoparticle-mediated siRNA delivery.
Wang, X., Yu, B., Wu, Y., Lee, R. J., & Lee, L. J. (2011) · PubMed · Cited by 41
Kadam, U. T., Jordan, K. P., & Croft, P. R. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2006.02.016 · Cited by 35
Rationale for immunological approaches to breast cancer therapy
Monnot, G., & Romero, P. J. (2017) · The Breast · doi:10.1016/j.breast.2017.06.009 · Cited by 35
Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer
Bryant, G., Wang, L., & Mulholland, D. J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071542 · Cited by 31
Cazzaniga, M. E., Biganzoli, L., Cortesi, L., Placido, S. D., Donadio, M., Fabi, A., Ferro, A., Generali, D., Lorusso, V., Milani, A., et al. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s189163 · Cited by 30
Goli, N., Bolla, P. K., & Talla, V. (2018) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2018.08.022 · Cited by 26
α-Actinin-4 confers radioresistance coupled invasiveness in breast cancer cells through AKT pathway
Desai, S., Barai, A., Bukhari, A. B., De, A., & Sen, S. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2017.10.006 · Cited by 24
ApoptomiRs of Breast Cancer: Basics to Clinics
Sharma, S., Patnaik, P. K., Aronov, S., & Kulshreshtha, R. (2016) · Frontiers in Genetics · doi:10.3389/fgene.2016.00175 · Cited by 22
Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy
Xu, M. M., Pu, Y., Weichselbaum, R. R., & Fu, Y. (2016) · Oncogene · doi:10.1038/onc.2016.231 · Cited by 21
Cited by
Fan, Z., Tang, P., Li, C., Yang, Q., Xu, Y., Su, C., & Li, L. (2023) · Journal of Oral Microbiology · doi:10.1080/20002297.2022.2145729 · Cited by 150
Parsaee, S., Jahani, N., Salehiniya, H., & Raeison, M. (2024) · Journal of Breast Diseases · doi:10.61186/ijbd.17.1.84
Metadata
- Authors
- Barzaman, K., Karami, J., Zarei, Z., Hosseinzadeh, A., Kazemi, M. H., Moradi-Kalbolandi, S., Safari, E., & Farahmand, L.
- Venue
- International Immunopharmacology
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 84
- Pages
- 106535
- ISSN
- 1567-5769 (ISSN-L)
- OpenAlex
- W3023752815
- Cited by
- 973
- References
- 121
- FWCI
- 23.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.